PT  - JOURNAL ARTICLE
AU  - Rahman, Mohammad Meshbahur
AU  - Bhattacharjee, Badhan
AU  - Farhana, Zaki
AU  - Hamiduzzaman, Mohammad
AU  - Chowdhury, Muhammad Abdul Baker
AU  - Hossain, Mohammad Sorowar
AU  - Siddiqee, Mahbubul H
AU  - Islam, Md. Ziaul
AU  - Raheem, Enayetur
AU  - Uddin, Md. Jamal
TI  - Prevalence and Integration of symptoms and comorbidities with age of the SARS-CoV-2 patients: a systematic evaluation and meta-analysis
AID  - 10.1101/2020.08.19.20177980
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.19.20177980
4099  - http://medrxiv.org/content/early/2020/10/01/2020.08.19.20177980.short
4100  - http://medrxiv.org/content/early/2020/10/01/2020.08.19.20177980.full
AB  - Background The COVID-19 affected millions of people, and the patients present a constellation of symptoms and comorbidities. We aimed to estimate the prevalence of reported symptoms and comorbidities and assess the correlation between a series of symptoms and comorbidities and age of the patients’ positive in COVID-19.Methods We performed a systematic review and meta-analysis [PROSPERO registration: CRD42020182677]. Databases [PubMed, SCOPUS, EMBASE, WHO, Semantic Scholar, and COVID-19 Primer] were searched for clinical studies published from January to April 2020. The pooled prevalence of symptoms and comorbidities were identified using the random effect model, and the multivariable factor analysis was performed to show the correlation between a group of symptoms and comorbidities and age of the COVID-19 patients.Findings Twenty-nine articles [China (24); Outside of China (5)], with 4,884 COVID-19 patients were included in this study. The meta-analysis investigated 33 symptoms, where fever [84%], cough/dry cough [61%], and fatigue/weakness [42%] were found more prevalent. Out of 43 comorbidities investigated, acute respiratory distress syndrome (ARDS) [61%], hypertension [23%] and diabetes [12%] were the most prevalent comorbid condition. The multivariable factor analysis showed positive association between a group of symptoms and comorbidities, and with the patients’ age. For example, the symptoms comprising fever, dyspnea/shortness of breath, nausea, vomiting, abdominal pain, dizziness, anorexia and pharyngalgia; and the comorbidities including diabetes, hypertension, coronary heart disease, COPD/lung disease and ARDS were positively correlated with the COVID-19 patient’s age.Interpretation Among 19 symptoms and 11 comorbidities investigated, a group of symptoms and comorbidities were found correlated with the patients infected in COVID-19.Summary boxWhat is already known?What is already known?Study on the correlation of symptoms and comorbidities with age of the COVID-19 patients are yet to be explored sufficiently.What are the new findings?What are the new findings?We investigated all the reported symptoms [33] and comorbidity [43] where fever [84%], cough/dry cough [61%], fatigue/weakness [42%] and dyspnea/shortness of breath [39%] were the most prevalent symptoms, and ARDS [61%], followed by hypertension [23%] and diabetes [12%] were the most prevalent comorbid condition.Key findings, a group of symptoms and comorbidities were positively correlated with the COVID-19 patients’ age.The symptoms comprising fever, dyspnea/shortness of breath, nausea, vomiting, abdominal pain, dizziness, anorexia and pharyngalgia; and the comorbidities including diabetes, hypertension, coronary heart disease, COPD/lung disease and ARDS were positively associated with the COVID-19 patient’s age.What do the new findings imply?What do the new findings imply?This efforts in determining the correlation of the frequent symptoms and comorbidities will help the clinicians and disease practitioners to implement patient-centred interventions.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a systematic review and clinical trail registration is not necessarily important here.Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=182677 Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not ApplicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full list of data and the data entries for all included studies is provided in the manuscript. No additional supporting data is available.